The prognostic value of CD30
The definitive role of prevalence and intensity of CD30 in prognosis is evolving. Where defined, the prognostic value of CD30 expression is variable and lymphoma subtype–specific.
In one study of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), expression of CD30 in ≥80% of cells was associated with an extremely poor prognosis:
High prevalence of CD30-positive cells has a variable association with prognosis in PTCL–NOS1,2
|Study||N||CD30 cutoff||CD30-positive prognosis||Statistically significant|
|Savage et al1||331||≥80% of cells CD30-positive||Poor||N/A|
|Bisig et al2||36||>75% of cells CD30-positive||Superior||Not significant|
In diffuse large B-cell lymphoma (DLBCL), CD30 expression is a favorable prognostic factor based on a large, multicenter study. Patients with >20% CD30-positive cells had a
Prognostic impact of CD30 expression in DLBCL3
- Savage KJ, Harris NL, Vose JM, et al; for International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
- Bisig B, de Reyniès A, Bonnet C, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250-1258.
- Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program study. Blood. 2013;121(14):2715-2724.
NCCN recommends CD30
The NCCN Guidelines* recommend CD30 testing for the differential diagnosis of Hodgkin and certain non-Hodgkin lymphomas...
The clinical relevance of CD30
Appropriate management of patients with lymphoma depends on an accurate diagnosis...
CD30 in NHL prognosis
The definitive role of prevalence and intensity of CD30 in prognosis is evolving...
Study finds CD30 in 17 cancers
In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated...
CD30 in Burkitt lymphoma
25% of Burkitt lymphoma cases express CD30. The endemic variant, African Burkitt lymphoma...
CD30 and overall survival in PTCL‑NOS
A recent study found that CD30 expression is an adverse predictor of survival in peripheral T-cell lymphoma...
CD30 screening in germ cell tumors
CD30 is strongly expressed in more than 95% of embryonal carcinomas, while other germ cell tumors lack CD30...
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.2.2013 and Hodgkin Lymphoma V.2.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed September 24, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.